AstraZeneca Pays $100M Upfront, Up to $2B Total for Jacobio’s Pan-KRAS Inhibitor JAB-23E73
AstraZeneca; Jacobio Pharma; JAB-23E73; pan-KRAS inhibitor; cancer drug; licensing deal; $100M upfront; $2B milestones
BioMarin Announces $4.8 Billion Acquisition of Amicus Therapeutics for Rare Disease Portfolio Expansion
BioMarin; Amicus Therapeutics; acquisition; $4.8B; Galafold; Pombiliti; Opfolda; rare diseases
FDA Approves Cytokinetics’ Myqorzo for Obstructive Hypertrophic Cardiomyopathy, Positioning It Against BMS’s Camzyos
FDA approval; Cytokinetics; Myqorzo; aficamten; obstructive hypertrophic cardiomyopathy; Bristol Myers Squibb; Camzyos
Bayer’s Finerenone Approved in Japan for Chronic Heart Failure Treatment
Finerenone; Kerendia; Japan approval; chronic heart failure; HFmrEF; HFpEF; Bayer; FINEARTS-HF
White House unveils nine new “most-favored-nation” drug pricing deals
most-favored-nation pricing; MFN; drug pricing; White House; Trump administration; pharmaceutical manufacturers; Ozempic; Wegovy; Eli Lilly; Novo Nordisk; prescription drug costs; US healthcare policy
FDA places partial clinical hold on Merck and Daiichi Sankyo’s I-DXd lung cancer trial after interstitial lung disease deaths
FDA partial clinical hold; ifinatamab deruxtecan; I-DXd; IDeate-Lung02; Merck; Daiichi Sankyo; small cell lung cancer; interstitial lung disease; grade 5 ILD; antibody-drug conjugate; clinical trial deaths
Recent Biotech News: Altimmune’s Pemvidutide Advances in MASH, Emerging China Obesity Players, and Ipsen Phase 2 Setback
Altimmune; pemvidutide; MASH; Phase 2b; IMPACT trial; FDA; China obesity; Ipsen; Phase 2 fail
Insmed Delivers Rare Disappointment as Brinsupri Flops in Mid-Stage Rhinosinusitis Study
Insmed; Brensocatib; Brinsupri; DPP1 inhibitor; chronic rhinosinusitis without nasal polyps; mid-stage trial; Phase 2b; nasal inflammation; trial failure; biotech stocks; INS1148 acquisition
Moderna Lands CEPI as New Backer for Its Pandemic Flu (H5 Bird Flu) Program
Moderna; CEPI; Coalition for Epidemic Preparedness Innovations; pandemic influenza; H5 bird flu; mRNA vaccine; Phase 3 trial; pandemic preparedness; vaccine development; funding
Endpoints News Topics at 2026 JPM Healthcare Conference: CEOs, Investors, China, and Beyond
JPM Healthcare Conference; Endpoints News; CEOs; investors; AI healthcare; biopharma; private equity